| Name | Title | Contact Details |
|---|
Adicet Bio, Inc. is a publicly held biotechnology company (Nasdaq: ACET) discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Cell Signaling Technology, Inc. is a Danvers, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our vision is to become the leading innovative global life-sciences company that unlocks the potential of T-cell biology and combines it with the power of T-cell engineering excellence to provide cures for patients. Through our model of seamless and rapid integration of research, translational medicine, manufacturing science, clinical development and customer-centric approaches, we will design and deliver enhanced state-of-the-art solutions for patients in a host of disease areas using Chimeric Antigen Receptors (CARs), Gene edited T-Cells, T regulatory cells (Treg), and engineered T Cell Receptors (TCRs)
Purdue Pharma L.P. is a privately held pharmaceutical company founded by physicians more than 60 years ago. We are committed to advancing the care of patients with innovative, quality products that make a positive impact on healthcare — and on lives. Purdue Pharma is part of a global network of independent associated companies that is known for pioneering research in chronic pain and opioids with abuse deterrent properties. The Company is engaged in the research, development, production, and marketing of prescription medicines and over-the-counter healthcare products. We are pursuing a promising pipeline of new medications through internal research & development and strategic industry partnerships. At Purdue, we embrace our mission to find, develop, and introduce innovative medicines that meet the evolving needs of healthcare professionals, patients and caregivers.
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio`s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world`s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.